Business
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5%Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11%Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11% to 18%Category I CPT codes and the related favorable physician fee payment levels took effect on Jan. 1, 2026FDA approved the BENEFIT-HF trial design in November and the Company has since applied to CMS
About this update from Cvrx, Inc.
[{"type":"image","alt":"CVRx, Inc.","displaySize":"","headline":null,"caption":"CVRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/df09df0c7616e5d7c04e1cae1c854256"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FkSLvnspvArMoZO8.ZuCnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/df09df0c7616e5d7c04e1cae1c854256","width":300,"height":119}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5%","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11%","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11% to 18%","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Category I CPT codes and the related favorable physician fee payment levels took effect on Jan. 1, 2026","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA approved the BENEFIT-HF trial design in November and the Company has since applied to CMS for coverage for the trial","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Debt facility amended to extend maturity date to 2031 and to increase the facility from the $50 million of term loans already drawn by an additional $50 million, of which $10 million was funded at closing","length":204,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":731,"olType":false},{"type":"text","content":"MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited fourth quarter and full year 2025 revenue results as well as provided a 2026 business outlook.","length":412,"tagName":"p"},{"type":"text","content":""We're pleased with our execution in 2025 as we delivered solid results while making significant strategic progress across the organization," said Kevin Hykes, P...